Brinzolamide

What it is and how it works

Mechanism of Action Carbonic anhydrase is an enzyme found in many tissues of the body, including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II, found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in IOP.

Mechanism class: Carbonic Anhydrase Inhibitors

Indications

Brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.

Dosage and administration (summary)

The recommended dose is one drop of brinzolamide ophthalmic suspension 1% in the affected eye(s) 3 times daily. Shake well before use. Brinzolamide ophthalmic suspension 1% may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 10 minutes apart. • Instill one drop in the affected eye(s) 3 times daily. • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 10 minutes apart.

Contraindications

Brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. Hypersensitivity to any component of this product.

Warnings and precautions

• Sulfonamide hypersensitivity reactions. • Corneal edema may occur in patients with low endothelial cell counts. Sulfonamide Hypersensitivity Reactions Brinzolamide ophthalmic suspension 1% is a sulfonamide and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of brinzolamide ophthalmic suspension 1%.

Pregnancy

Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. In reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (RHOD) based on mg/kg.

Storage and supply

Brinzolamide ophthalmic suspension 1% is supplied in plastic dispensers with a controlled dispensing-tip as follows: 10 mL NDC 0781-6014-70 15 mL NDC 0781-6014-85 Storage and Handling Store brinzolamide ophthalmic suspension 1% at 4°C to 30°C (39°F to 86°F). Shake well before use.

Source: Brinzolamide (Brinzolamide) — US FDA prescribing information, 2023-06-30, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.